Journal of the American Society of Nephrology
2006 JASN IMPACT FACTOR 7.371 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on February 13, 2008
J Am Soc Nephrol 19: 999-1007, 2008
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2007060693

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2007060693v1
19/5/999    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Vogt, L.
Right arrow Articles by Navis, G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vogt, L.
Right arrow Articles by Navis, G.

CLINICAL RESEARCH

Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan

Liffert Vogt*, Femke Waanders*, Frans Boomsma{dagger}, Dick de Zeeuw*,{ddagger} and Gerjan Navis*,{ddagger}

* Department of Internal Medicine, Division of Nephrology and {ddagger} Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, and {dagger} Department of Internal Medicine, Section of Vascular Pharmacology, Erasmus Medical Center, Rotterdam, Netherlands

Correspondence: Prof. Dr. Gerjan Navis, University Medical Center Groningen, Department of Internal Medicine, Division of Nephrology, Hanzeplein 1, 9713 GZ Groningen, Netherlands. Phone: +31-50-361-2955; Fax: +31-50-361-9310; E-mail: G.J.Navis{at}int.umcg.nl

Received for publication June 21, 2007. Accepted for publication November 6, 2007.

There is large interindividual variability in the antiproteinuric response to blockade of the renin-angiotensin-aldosterone system (RAAS). A low-sodium diet or addition of diuretics enhances the effects of RAAS blockade on proteinuria and BP, but the efficacy of the combination of these interventions is unknown. Therefore, this randomized, double-blind, placebo-controlled trial to determine the separate and combined effects of a low-sodium diet and hydrochlorothiazide (HCT) on proteinuria and BP was performed. In 34 proteinuric patients without diabetes, mean baseline proteinuria was 3.8 g/d, and this was reduced by 22% by a low-sodium diet alone. Losartan monotherapy reduced proteinuria by 30%, and the addition of a low-sodium diet led to a total reduction by 55% and the addition of HCT to 56%. The combined addition of HCT and a low-sodium diet reduced proteinuria by 70% from baseline (all P < 0.05). Reductions in mean arterial pressure showed a similar pattern (all P < 0.05). In addition, individuals who did not demonstrate an antiproteinuric response to losartan monotherapy did respond when a low-sodium diet or a diuretic was added. In conclusion, a low-sodium diet and HCT are equally efficacious in reducing proteinuria and BP when added to a regimen containing losartan and especially seem to benefit individuals who are resistant to RAAS blockade. Combining these interventions in sodium status is an effective method to maximize the antiproteinuric efficacy of RAAS blockade.







HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP